Department of Ophthalmology, Centro Hospitalar Universitário Do Porto, Largo Do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Department of Biomedicine - Unit of Anatomy, Faculty of Medicine of University of Porto, Porto, Portugal.
Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2221-2233. doi: 10.1007/s00417-023-06023-2. Epub 2023 Mar 8.
Retinal toxicity with long-term hydroxychloroquine (HCQ) treatment is a major concern. This systematic review aims to assess the application of optical coherence tomography angiography (OCTA) to detect microvascular alterations in patients under HCQ.
PubMed, Scopus, Web of Science, and Cochrane Library databases were systematically searched until January 14, 2023. Studies using OCTA as a primary diagnostic method to evaluate the macular microvasculature of HCQ users were included. Primary outcomes were macular vessel density (VD) and foveal avascular zone (FAZ) at the superficial (SCP) and deep (DCP) capillary plexus. Meta-analysis was performed using a random-effects model.
Of 211 screened abstracts, 13 were found eligible, enrolling 989 eyes from 778 patients. High-risk patients due to longer duration of treatment presented lower VD in the retinal microvasculature than those with low-risk in SCP (P = 0.02 in fovea; P = 0.004 in parafovea) and in DCP (P = 0.007 in fovea; P = 0.01 in parafovea). When compared with healthy controls, HCQ users had lower VD in both plexus-no quantitative synthesis was presented.
Microvascular changes were found in autoimmune patients under HCQ treatment without any documented retinopathy. However, the evidence produced so far does not allow to draw conclusion concerning the effect of drug as studies were not controlled for disease duration.
长期羟氯喹(HCQ)治疗的视网膜毒性是一个主要关注点。本系统评价旨在评估光学相干断层扫描血管造影(OCTA)在检测接受 HCQ 治疗的患者微血管改变中的应用。
系统检索了 PubMed、Scopus、Web of Science 和 Cochrane Library 数据库,检索截至 2023 年 1 月 14 日。纳入使用 OCTA 作为主要诊断方法评估 HCQ 使用者黄斑微血管的研究。主要结局指标为浅层(SCP)和深层(DCP)毛细血管丛的黄斑血管密度(VD)和中心无血管区(FAZ)。使用随机效应模型进行荟萃分析。
在 211 篇筛选的摘要中,发现 13 篇符合纳入标准,共纳入 778 例患者的 989 只眼。由于治疗时间较长而处于高风险的患者,其视网膜微血管的 SCP (在中心凹处 P=0.02;在旁中心凹处 P=0.004)和 DCP (在中心凹处 P=0.007;在旁中心凹处 P=0.01)中的 VD 均低于低风险患者。与健康对照组相比,HCQ 使用者在两个丛中的 VD 均较低-但未进行定量合成。
在没有任何记录的视网膜病变的情况下,自身免疫性疾病患者在接受 HCQ 治疗后出现了微血管变化。然而,由于目前的研究没有针对疾病持续时间进行对照,因此无法得出关于药物影响的结论。